Nothing Special   »   [go: up one dir, main page]

MA30487B1 - Nouveaux composes heterocycliques - Google Patents

Nouveaux composes heterocycliques

Info

Publication number
MA30487B1
MA30487B1 MA31430A MA31430A MA30487B1 MA 30487 B1 MA30487 B1 MA 30487B1 MA 31430 A MA31430 A MA 31430A MA 31430 A MA31430 A MA 31430A MA 30487 B1 MA30487 B1 MA 30487B1
Authority
MA
Morocco
Prior art keywords
heterocyclic compounds
new heterocyclic
derivatives
pyridinone
pyridone
Prior art date
Application number
MA31430A
Other languages
English (en)
Inventor
Calderon Jose Maria Bueno
Gonzalo Jesus Chicharro
Garcia Milagros Lorenzo
Chinchon M Pilar Manzano
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP06381025A external-priority patent/EP1862459A1/fr
Priority claimed from EP07380072A external-priority patent/EP1967515A1/fr
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of MA30487B1 publication Critical patent/MA30487B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/68—One oxygen atom attached in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

Composés hétérocycliques nouveaux Des dérivés de 4-pyridone (4-pyridinone) de formule (I) et leurs dérivés pharmaceutiquement acceptables, des procédés pour leur préparation, des formulations pharmaceutiques les contenant et leur utilisation en chimiothérapie de certaines infections parasitaires telles que le paludisme sont proposés.
MA31430A 2006-05-31 2008-12-01 Nouveaux composes heterocycliques MA30487B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP06381025A EP1862459A1 (fr) 2006-05-31 2006-05-31 Nouveaux composés hétérocycliques
EP07380072A EP1967515A1 (fr) 2007-03-08 2007-03-08 Composés hétérocycliques

Publications (1)

Publication Number Publication Date
MA30487B1 true MA30487B1 (fr) 2009-06-01

Family

ID=38480438

Family Applications (1)

Application Number Title Priority Date Filing Date
MA31430A MA30487B1 (fr) 2006-05-31 2008-12-01 Nouveaux composes heterocycliques

Country Status (17)

Country Link
US (2) US7674808B2 (fr)
EP (1) EP2024332A1 (fr)
JP (1) JP2009538873A (fr)
KR (1) KR20090012342A (fr)
AR (1) AR060974A1 (fr)
AU (1) AU2007267093A1 (fr)
BR (1) BRPI0711783A2 (fr)
CA (1) CA2653872A1 (fr)
CR (1) CR10492A (fr)
EA (1) EA200870545A1 (fr)
IL (1) IL195158A0 (fr)
MA (1) MA30487B1 (fr)
MX (1) MX2008015291A (fr)
NO (1) NO20085087L (fr)
PE (1) PE20080453A1 (fr)
TW (1) TW200817331A (fr)
WO (1) WO2007138048A1 (fr)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050158294A1 (en) 2003-12-19 2005-07-21 The Procter & Gamble Company Canine probiotic Bifidobacteria pseudolongum
US8877178B2 (en) 2003-12-19 2014-11-04 The Iams Company Methods of use of probiotic bifidobacteria for companion animals
CA2607949C (fr) 2005-05-31 2012-09-25 Thomas William-Maxwell Boileau Bifidobacteries de probiotiques felins
AR052472A1 (es) 2005-05-31 2007-03-21 Iams Company Lactobacilos probioticos para felinos
CA2673465A1 (fr) 2007-02-01 2008-08-07 The Iams Company Procede de reduction de l'inflammation et du stress chez un mammifere
JP2011504914A (ja) * 2007-11-30 2011-02-17 グラクソ グループ リミテッド 抗マラリア化合物の結晶形態
US9771199B2 (en) * 2008-07-07 2017-09-26 Mars, Incorporated Probiotic supplement, process for making, and packaging
US9232813B2 (en) * 2008-07-07 2016-01-12 The Iams Company Probiotic supplement, process for making, and packaging
EP2246329A1 (fr) 2009-01-19 2010-11-03 Glaxo Group Limited Dérivés de la 4(1H)-pyridinone et leur utilisation contre la malaria
WO2010081904A1 (fr) 2009-01-19 2010-07-22 Glaxo Group Limited Dérivés de 4(1h)-pyridinone et leur utilisation comme agents antipaludiques
TW201039834A (en) 2009-02-20 2010-11-16 Glaxo Group Ltd Novel heterocyclic compounds
WO2010142741A1 (fr) * 2009-06-12 2010-12-16 Glaxo Group Limited Phénylpyridylpyridones destinées à être utilisées comme agents antipaludéens
US10104903B2 (en) 2009-07-31 2018-10-23 Mars, Incorporated Animal food and its appearance
US9801627B2 (en) * 2014-09-26 2017-10-31 Ethicon Llc Fastener cartridge for creating a flexible staple line
JOP20180072A1 (ar) 2014-09-11 2019-01-30 Lilly Co Eli علاج الأعراض المرتبطة بالعلاج بالحرمان من الأندروجين
WO2016169908A1 (fr) * 2015-04-21 2016-10-27 Glaxosmithkline Intellectual Property Development Limited Dérivés d'uracile pour le traitement de la malaria
GB201809627D0 (en) * 2018-06-12 2018-07-25 Biorelevant Com Ltd Methods for preparing buffer solutions suitable for in vitro drug dissolution testing, drug solubility testing and/or drug profiling

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9005518D0 (en) * 1990-03-12 1990-05-09 Wellcome Found Heterocyclic compounds
US5403934A (en) * 1990-03-12 1995-04-04 Burroughs Wellcome Co. Heterocyclic compounds
GB9100465D0 (en) * 1991-01-09 1991-02-20 Hider Robert C Pharmaceutical compositions

Also Published As

Publication number Publication date
US7674808B2 (en) 2010-03-09
AU2007267093A1 (en) 2007-12-06
MX2008015291A (es) 2008-12-12
US20080021073A1 (en) 2008-01-24
EA200870545A1 (ru) 2009-12-30
TW200817331A (en) 2008-04-16
US7629365B2 (en) 2009-12-08
CR10492A (es) 2009-01-27
EP2024332A1 (fr) 2009-02-18
BRPI0711783A2 (pt) 2011-11-29
IL195158A0 (en) 2009-08-03
CA2653872A1 (fr) 2007-12-06
NO20085087L (no) 2009-02-20
KR20090012342A (ko) 2009-02-03
US20070281977A1 (en) 2007-12-06
WO2007138048A1 (fr) 2007-12-06
JP2009538873A (ja) 2009-11-12
PE20080453A1 (es) 2008-05-29
AR060974A1 (es) 2008-07-23

Similar Documents

Publication Publication Date Title
MA30487B1 (fr) Nouveaux composes heterocycliques
MA29791B1 (fr) Composes therapeutiques.
MA28270A1 (fr) Pyrido [2, 3-D] pyrimidine-2, 4-diamines servant d'inhibiteurs de PDE 2
MA31754B1 (fr) Cis-imidazolines chirales
MA45223A (fr) Nouveaux dérivés de pipéridinyle subsitués par (hétéro)aryle, leur procédé de préparation et compositions pharmaceutiques les contenant
TNSN07022A1 (fr) Derives de pyridine
TN2009000450A1 (fr) Derives de pyridine
MA38138A1 (fr) Dérivés inédits de quinolone
EA201490477A1 (ru) Фармацевтические составы, содержащие пропиленгликоль-гидрат дапаглифлозина
TN2009000033A1 (fr) Derives de pyrazole servant d'inhibiteurs du cytochrome p450
MA29926B1 (fr) Derives de pyrazine
MA31290B1 (fr) Derives d'amino-pyridine comme agonistes du recepteur s1p1/edg1
MA34604B1 (fr) Derives de la pyrazine en tant que bloqueurs de l'enac
MA27389A1 (fr) Derives de benzimidazole nouveaux utiles comme agents antiproliferatifs.
MA30226B1 (fr) Agents cytotoxiques comprenant de nouveaux derives de tomaymycine et leur utilisation therapeutique.
EA201001368A1 (ru) Гетероциклические производные мочевины и способы их применения-211
TNSN07476A1 (fr) Derives de n-(pyridine -2- yl) - sulfonamide
MA31142B1 (fr) Derives heteroaryles de pyrrolidinyl et piperdinyl cetones.
EA200501326A1 (ru) Пиримидины и триазины, ингибирующие репликацию вич
JP2022539523A (ja) カンナビノイド抱合分子
MA28675B1 (fr) Piperazinediones utilises en tant qu'antagonistes du recepteur de l'oxytocine
MA30478B1 (fr) Composition comprenant au moins un alcool aliphatique superieur et un extrait de griffonia simplicifolia.
TN2016000014A1 (fr) Nouveaux dérivés d'indolizine, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent
MA30410B1 (fr) Dimeres de derives d'artemisinine, leur preparation et leur application en therapeutique.
MA49127B1 (fr) Dérivés d'indole n-substitués